Stoke Therapeutics to Present at Upcoming Investor Conferences
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences, which will each be conducted in a fireside chat format:
Stifel 3rd Annual CNS Day
Date: Wednesday, March 31, 2021
Time: 2:00 p.m. ET
20th Annual Needham Virtual Healthcare Conference
Date: Thursday, April 15, 2021
Time: 12:45 p.m. ET
A live audio webcast of each fireside chat will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the fireside chats.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company’s first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005229/en/